Characteristics
|
Hazard ratio (95% CI)
|
P value*
|
---|
AJCC Tumor stage
|
2.775 (1.815-4.243)
|
< 0.001
|
Portal vein thrombosis
|
1.573 (0.912-2.715)
|
0.103
|
Serum AFP (≥ 400 ng/mL)
|
1.153 (0.688-1.919)
|
0.584
|
Serum PIVKA-II (≥ 300 mAU/mL)
|
2.718 (1.535-4.812)
|
0.001
|
Platelet count (≤ 130 × 103/μL)
|
1.830 (1.130-2.964)
|
0.014
|
BCLC Tumor stage
|
1.210 (1.047-1.400)
|
0.010
|
Portal vein thrombosis
|
1.934 (1.094-3.422)
|
0.023
|
Serum AFP (≥ 400 ng/mL)
|
1.470 (0.888-2.433)
|
0.133
|
Serum PIVKA-II (≥ 300 mAU/mL)
|
3.688 (2.073-6.560)
|
< 0.001
|
Platelet count (≤ 130 × 103/μL)
|
1.911 (1.187-3.076)
|
0.008
|
- Abbreviation: AFP, alpha-fetoprotein; PIVKA-II, Protein induced by vitamin K absence or antagonist-II;
- *P-values for each clinical variable calculated using Cox regression analysis.